Form 8-K Vitae Pharmaceuticals, For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS
August 4, 2015 4:20 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) reported Q2 EPS of ($0.45), in-line with the analyst estimate of ($0.45). Revenue for the quarter came in at $161.6 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.
... More